Transforming growth factor-β coordinately induces suppressor of cytokine signaling 3 and leukemia inhibitory factor to suppress osteoclast apoptosis

Endocrinology

Volumn 151, Issue 4, 2010, Pages 1713-1722

  Ruan, Ming ^a   Pederson, Larry ^a   Bradley, Elizabeth W ^b   Bamberger, Ana Maria ^c   Oursler, Merry Jo ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; LEUKEMIA INHIBITORY FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; STAT1 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; ENZYME REPRESSION; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION;

ANALYSIS OF VARIANCE; ANIMALS; APOPTOSIS; BCL-X PROTEIN; BLOTTING, WESTERN; CELL SURVIVAL; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; LEUKEMIA INHIBITORY FACTOR; MICE; NF-KAPPA B; OSTEOCLASTS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SMAD PROTEINS; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 77950208124     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2009-0813     Document Type: Article

References (53)

1. GuiseTA,MundyGR1998 Cancer and bone. Endocr Rev 19:18-54
2. Michigami T, Ihara-Watanabe M, Yamazaki M, Ozono K 2001 Receptor activator of nuclear factor κB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. Cancer Res 61:1637-1644
3. Roodman GD 1995 Osteoclast function in Paget's disease and multiple myeloma. Bone 17:57S-61S
4. Winding B, Misander H, Sveigaard C, Therkildsen B, Jakobsen M, Overgaard T, Oursler MJ, Foged NT 2000 Human breast cancer cells induced angiogenesis, recruitment, and activation of osteoclasts in osteolytic metastasis. J Cancer Res Clin Oncol 126:631-640
5. GoltzmanD2001 Osteolysis and cancer. J Clin Invest 107:1219-1220
6. Janssens K, ten Dijke P, Janssens S, Van HulW2005 Transforming growth factor-β1 to the bone. Endocr Rev 26:743-774
7. Kanaan RA, KanaanLA2006 Transforming growth factor β1, bone connection. Med Sci Monit 12:RA164-RA169
8. Fox SW, Evans KE, Lovibond AC 2008 Transforming growth factor-β enables NFATc1 expression during osteoclastogenesis. Biochem Biophys Res Commun 366:123-128
9. Karst M, Gorny G, Galvin RJ, OurslerMJ2004 Roles of stromal cell RANKL,OPG,andM-CSFexpression in biphasic TGF-βregulation of osteoclast differentiation. J Cell Physiol 200:99-106
10. Mohammad KS, Chen CG, Balooch G, Stebbins E, McKenna CR, Davis H, Niewolna M, Peng XH, Nguyen DH, Ionova-Martin SS, Bracey JW, Hogue WR, Wong DH, Ritchie RO, Suva LJ, Derynck R, Guise TA, Alliston T 2009 Pharmacologic inhibition of the TGF-β type I receptor kinase has anabolic and anti-catabolic effects on bone. PLoS ONE 4:e5275
11. Futakuchi M, Nannuru KC, Varney ML, Sadanandam A, Nakao K, Asai K, Shirai T, Sato SY, Singh RK 2009 Transforming growth factor-β signaling at the tumor-bone interface promotes mammary tumor growth and osteoclast activation. Cancer Sci 100:71-81
12. Gingery A, BradleyEW,Pederson L,RuanM,HorwoodNJ, Oursler MJ 2008 TGF-β coordinately activates TAK1/MEK/AKT/NFκB and SMAD pathways to promote osteoclast survival. Exp Cell Res 314:2725-2738
13. Shi Y, Massagué J 2003 Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 113:685-700
14. Feng XH, Derynck R 2005 Specificity and versatility in TGF-β signaling through Smads. Annu Rev Cell Dev Biol 21:659-693
15. Moustakas A, Heldin CH2005 Non-Smad TGF-β signals. J Cell Sci 118:3573-3584
16. Derynck R, Zhang YE 2003 Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 425:577-584
17. Borton AJ, Frederick JP, Datto MB, Wang XF, Weinstein RS 2001 The loss of Smad3 results in a lower rate of bone formation and osteopenia through dysregulation of osteoblast differentiation and apoptosis. J Bone Miner Res 16:1754-1764
18. Auernhammer CJ, Melmed S 2000 Leukemia-inhibitory factor-neuro-immune modulator of endocrine function. Endocr Rev 21:313-345
19. Derigs HG, Boswell HS 1993 LIF mRNA expression is transcriptionally regulated in murine bone marrow stromal cells. Leukemia 7:630-634
20. Hamilton JA, Waring PM, Filonzi EL 1993 Induction of leukemia inhibitory factor in human synovial fibroblasts by IL-1 and tumor necrosis factor-α. J Immunol 150:1496-1502
21. Campbell IK, Waring P, Novak U, Hamilton JA 1993 Production of leukemia inhibitory factor by human articular chondrocytes and cartilage in response to interleukin-1 and tumor necrosis factor α. Arthritis Rheum 36:790-794
22. Elias JA, Zheng T, Whiting NL, Marcovici A, Trow TK 1994 Cytokine-cytokine synergy and protein kinase C in the regulation of lung fibroblast leukemia inhibitory factor. Am J Physiol 266:L426-L435
23. Grosset C, Jazwiec B, Taupin JL, Liu H, Richard S, Mahon FX, Reiffers J, Moreau JF, Ripoche J 1995 In vitro biosynthesis of leukemia inhibitory factor/human interleukin for DA cells by human endothelial cells: differential regulation by interleukin-1α and glucocorticoids. Blood 86:3763-3770
24. Carlson CD, Bai Y, Ding M, Jonakait GM, Hart RP 1996 Interleukin-1 involvement in the induction of leukemia inhibitory factor mRNA expression following axotomy of sympathetic ganglia. J Neuroimmunol 70:181-190
25. Chabaud M, Fossiez F, Taupin JL, Miossec P 1998 Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J Immunol 161:409-414
26. CarterDA1995 Leukaemia inhibitory factor expression in cultured rat anterior pituitary is regulated by glucocorticoids. J Neuroendocrinol 7:623-628
27. Grosset C, Taupin JL, Lemercier C, Moreau JF, Reiffers J, Ripoche J 1999 Leukaemia inhibitory factor expression is inhibited by glucocorticoids through post-transcriptional mechanisms. Cytokine 11:29-36
28. Park JI, Strock CJ, Ball DW, Nelkin BD 2003 The Ras/Raf/MEK/ extracellular signal-regulated kinase pathway induces autocrine-paracrine growth inhibition via the leukemia inhibitory factor/JAK/STAT pathway. Mol Cell Biol 23:543-554
29. Moon C, Liu BQ, Kim SY, Kim EJ, Park YJ, Yoo JY, Han HS, Bae YC, Ronnett GV 2009 Leukemia inhibitory factor promotes olfactory sensory neuronal survival via phosphoinositide 3-kinase pathway activation and Bcl-2. J Neurosci Res 87:1098-1106
30. Slaets H, Dumont D, Vanderlocht J, Noben JP, Leprince P, Robben J, Hendriks J, Stinissen P, Hellings N 2008 Leukemia inhibitory factor induces an antiapoptotic response in oligodendrocytes through Akt-phosphorylation and up-regulation of 14-3-3. Proteomics 8:1237-1247
31. Lu Y, Fukuyama S, Yoshida R, Kobayashi T, Saeki K, Shiraishi H, Yoshimura A, Takaesu G 2006 Loss of SOCS3 gene expression converts STAT3 function from anti-apoptotic to pro-apoptotic. J Biol Chem 281:36683-36690
32. Abell K, Bilancio A, Clarkson RW, Tiffen PG, Altaparmakov AI, Burdon TG, Asano T, Vanhaesebroeck B, Watson CJ 2005 Stat3-induced apoptosis requires a molecular switch in PI(3)K subunit composition. Nat Cell Biol 7:392-398
33. Abell K, Watson CJ 2005 The Jak/Stat pathway: a novel way to regulate PI3K activity. Cell Cycle 4:897-900
34. Gingery A, Bradley E, Shaw A, Oursler MJ 2003 Phosphatidylinositol 3-kinase coordinately activates the MEK/ERK and AKT/NFκB pathways to maintain osteoclast survival. J Cell Biochem 89:165-179
35. Bamberger AM, Erdmann I, Bamberger CM, Jenatschke SS, Schulte HM 1997 Transcriptional regulation of the human 'leukemia inhibitory factor' gene: modulation by glucocorticoids and estradiol. Mol Cell Endocrinol 127:71-79
36. Johnsen SA, Subramaniam M, Janknecht R, Spelsberg TC 2002 TGFβ inducible early gene enhances TGFβ/Smad-dependent transcriptional responses. Oncogene 21:5783-5790
37. Bozec A, Bakiri L, Hoebertz A, Eferl R, Schilling AF, Komnenovic V, Scheuch H, Priemel M, Stewart CL, Amling M, Wagner EF 2008 Osteoclast size is controlled by Fra-2 through LIF/LIF-receptor signalling and hypoxia. Nature 454:221-225
38. Stover DG, Bierie B, MosesHL2007Adelicate balance: TGF-β and the tumor microenvironment. J Cell Biochem 101:851-861
39. Lentzsch S, ChatterjeeM,GriesM,BommertK, Gollasch H,Dörken B, Bargou RC 2004 PI3-K/AKT/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells. Leukemia 18:1883-1890
40. Tanaka T, Morita E, Mihara S, Kanno M, Yamamoto S 2001 Identification of leukemia inhibitory factor as a potent mast cell growth-enhancing factor produced by mouse keratinocyte cell line, KCMH-1. Arch Dermatol Res 293:18-25
41. Peñuelas S, Anido J, Prieto-Sánchez RM, Folch G, Barba I, Cuartas I, García-Dorado D, Poca MA, Sahuquillo J, Baselga J, Seoane J 2009 TGF-β increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell 15:315-327
42. Morita Y, Manganaro TF, Tao XJ, Martimbeau S, Donahoe PK, Tilly JL 1999 Requirement for phosphatidylinositol-3′-kinase in cytokine-mediated germ cell survival during fetal oogenesis in the mouse. Endocrinology 140:941-949
43. Izumi M, Masaki M, Hiramoto Y, Sugiyama S, Kuroda T, Terai K, Hori M, Kawase I, Hirota H 2006 Cross-talk between bone morphogenetic protein 2 and leukemia inhibitory factor through ERK 1/2 and Smad1 in protection against doxorubicin-induced injury of cardiomyocytes. J Mol Cell Cardiol 40:224-233
44. Fujio Y, Kunisada K, Hirota H, Yamauchi-Takihara K, Kishimoto T 1997 Signals through gp130 upregulate bcl-x gene expression via STAT1-binding cis-element in cardiac myocytes. J Clin Invest 99: 2898-2905
45. Schweizer U, Gunnersen J, Karch C, Wiese S, Holtmann B, Takeda K, Akira S, Sendtner M 2002 Conditional gene ablation of Stat3 reveals differential signaling requirements for survival of motoneurons during development and after nerve injury in the adult. J Cell Biol 156:287-297
46. Cheema SS, Richards L, Murphy M, Bartlett PF 1994 Leukemia inhibitory factor prevents the death of axotomised sensory neurons in the dorsal root ganglia of the neonatal rat. J Neurosci Res 37: 213-218
47. Cheema SS, Richards LJ, Murphy M, Bartlett PF 1994 Leukaemia inhibitory factor rescues motoneurones from axotomy-induced cell death. Neuroreport 5:989-992
48. Kurek JB, Bennett TM, Bower JJ, Muldoon CM, Austin L 1998 Leukaemia inhibitory factor (LIF) production in a mouse model of spinal trauma. Neurosci Lett 249:1-4
49. Murphy M, Reid K, Brown MA, Bartlett PF 1993 Involvement of leukemia inhibitory factor and nerve growth factor in the development of dorsal root ganglion neurons. Development 117:1173-1182
50. Oberle S, Schober A, Meyer V, Holtmann B, Henderson C, Sendtner M, Unsicker K 2006 Loss of leukemia inhibitory factor receptor β or cardiotrophin-1 causes similar deficits in preganglionic sympathetic neurons and adrenal medulla. J Neurosci 26:1823-1832
51. Whitlon DS, Ketels KV, Coulson MT,Williams T, Grover M,Edpao W, Richter CP 2006 Survival and morphology of auditory neurons in dissociated cultures of newborn mouse spiral ganglion. Neuroscience 138:653-662
52. Waterhouse NJ, Sedelies KA, Trapani JA 2006 Role of Bid-induced mitochondrial outer membrane permeabilization in granzyme B-induced apoptosis. Immunol Cell Biol 84:72-78
53. Oursler MJ 1994 Osteoclast synthesis and secretion and activation of latent transforming growth factor β. J Bone Miner Res 9:443-452